Recombinant Human Eotaxin (CCL11) Protein (GST)

Name: Recombinant Human Eotaxin (CCL11) Protein (GST)
Brand: Beta LifeScience
SKU: BLC-09231P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Buy cytokines, chemokines, and growth factors for research online, Chemokines and receptors – essential regulators of immune response, High-quality cytokines for advanced research, High-quality recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Eotaxin (CCL11) Protein (GST) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P51671
Target Symbol	CCL11
Synonyms	C-C motif chemokine 11; CCL 11; CCL11; CCL11_HUMAN; chemokine (C-C motif) ligand 11; Chemokine C C motif ligand 11; Chemokine CC Motif Ligand 11; Chemokine ligand 11; Eosinophil chemotactic protein; Eotaxin; eotaxin-1; MGC22554; SCYA 11; SCYA11; Small inducible cytokine A11; Small inducible cytokine subfamily A (Cys Cys) member 11; small inducible cytokine subfamily A (Cys-Cys); member 11 (eotaxin); Small inducible cytokine subfamily A member 11; Small-inducible cytokine A11
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-GST
Target Protein Sequence	GPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP
Expression Range	1-97aa
Protein Length	Full Length
Mol. Weight	35.4kDa
Research Area	Immunology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10610 OMIM: 601156 KEGG: hsa:6356 STRING: 9606.ENSP00000302234 UniGene: PMID: 28634890 analyzed the genotypes of 6 tag SNPs in the CCL11 gene (rs1129844, rs17809012, rs1860183, rs1860184, rs4795898, and rs4795895) in a case control study. We found the GG genotype of rs4795895 was significantly associated with increased risk of lacunar stroke and the GA genotype of rs17809012 was associated with a significant increase in risk of LAA stroke PMID: 28873081 CCL11 promotor polymorphism is associated with increased risk for the development of schizophrenia in a Korean population. PMID: 29477870 Findings suggest that CCL11-CCR3 binding is involved in the progression of GBM. PMID: 27119233 There were no significant differences in GE area of infertile and fertile women. C-C motif chemokine 11 (P=0.048), TGFalpha (P=0.049), IFNgamma (P=0.033) and interleukin-1 alpha (P=0.047) were significantly elevated in uterine lavage from infertile women <35years compared to fertile but not in women 35years PMID: 27525354 eotaxin promotes proliferation in vascular smooth muscle cells and triggers oxidative stress in a NADPH oxidase dependent manner. PMID: 27681294 a receiver operating characteristic (ROC) curve analysis demonstrated CSF CCL11 accurately distinguished CTE subjects from non-athlete controls and AD subjects PMID: 28950005 These studies characterized serum and intestinal wall eotaxin-1 levels in various inflammatory bowel disease patients and to explore the effect of targeting eotaxin-1 by specific antibodies in dextran sodium sulfate-induced colitis model. PMID: 26874691 this study shows that expression of CCL11 is increased in eosinophilic myocarditis patients compared to chronic lymphocytic myocarditis patients PMID: 27621211 Review: eotaxins (CCL11, CCL24, and CCL26) play key role(s) during symptomatic inflammatory responses raised in response to allergic crisis of allergic asthma and atopic dermatitis PMID: 26861136 increased amounts released by neutrophils from fibromyalgia patients PMID: 26341115 Eotaxin measured on the day of birth is useful for identifying extremely low birth weight infants at risk of bronchopulmonary dysplasia/death. PMID: 26270578 The results of this study suggested that eotaxin-1 as a novel modifier of Alzheimer's disease age at onset and open potential avenues for therapy. PMID: 26324103 ANDV caused long-term elevated levels of eotaxin-1, IL-6, IL-8, IP-10, and VEGF-A that peaked 20-25 days after infection PMID: 26907493 The A allele in eotaxin 67 G/A polymorphism is associated with worse survival in CAD patients. PMID: 26491210 Findings demonstrate a link between CCL11 and primary Sjogren's syndrome disease activity and lymphoma. PMID: 26359802 Serum and urinary CCL11 were decreased in patients with prostate cancer compared with controls. PMID: 26306920 Results show the structure of CCL11 bound to the sulfated N-terminal region of its receptor CCR3 and show that intact CCR3 is sulfated and sulfation enhances receptor activity. PMID: 25450766 SF of BC OA displayed significantly higher concentrations for a number of proinflammatory cytokines [CXCL1, eotaxin, interferon (IFN)-gamma, interleukin (IL)-7, IL-8, IL-9, IL-12]. PMID: 25393692 Taken together, these findings indicate that inhibiting IL-4-induced eotaxin-1 expression by synephrine occurs primarily through the suppression of eosinophil recruitment, which is mediated by inhibiting STAT6 phosphorylation. PMID: 25111027 eotaxin-1 increases MMP-3 expression via the CCR3-ERK pathway, thereby promoting prostate cancer cell invasion and migration. PMID: 24604010 the CCL11 GG genotype is a significant risk factor for ischemic as well as hemorrhagic stroke. Further, the frequency of the GG genotype was observed to be higher in hemorrhagic stroke patients in comparison with ischemic stroke. PMID: 25237944 CCL11 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249 thi is a study of the interaction between vCCI and eotaxin-1 (CCL11), a CC chemokine that is an important factor in the asthma response. PMID: 24482230 Cannabis use was found to increase CCL11 plasma levels and the effects were reversed when cannabis use ceases. PMID: 23820464 CCL11, CCL24, and CCL26 are increased in TB patients; hence, it seems that TB suppresses Th1 and the classic function of macrophages subsequently by inducing the chemokines' expression PMID: 24600981 CCL11, CCL24, and CCL26 has a role in the recruitment of extravillous trophoblast into decidual tissue and vessels. PMID: 23477905 CCL11 contributes to eosinophil recruitment in UC and that intestinal myeloid cells are a source of CCL11. PMID: 23904440 These data uncover a previously unknown role for NRF2 in regulating Eotaxin-1 expression and further the mechanistic understanding of this pathway in modulating inflammatory lung disease. PMID: 23061798 The impact of three single-nucleotide polymorphisms in eotaxin (SCYA11) gene promoter (-426C>T and -384A>G) and first exon (67G>A) and recently described hexanucleotide (GAAGGA)(n) 10.9 kb upstream on coronary atherosclerosis was investigated. PMID: 22773402 Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). PMID: 23059958 The Marfan syndrome patients with lowest mental quality of life and vitality scores had high levels of CCL11 cytokine. PMID: 23049769 Study found that the plasma concentration of eotaxin was associated with the clinical severity of chronic rhinosinusitis in Taiwanese patients. PMID: 22271279 The level of eotaxin expression and inflammatory cell count were measured in the material from nasal brushing in healthy controls and in patients with allergic rhinitis, asthma, and chronic obstructive pulmonary disease. PMID: 22846146 the eotaxin/CCL11-CCR3 axis is active in idiopathic retroperitoneal fibrosis (IRF) and may contribute to its pathogenesis; the TTCCAT haplotype within the CCL11 gene is significantly associated with IRF PMID: 23114905 Serum CCL17, IL-8, and eotaxin levels were significantly increased in eosinophilic subjects as compared to normal controls, but were similar between Churg-syndrome and hypereosinophilic syndrome. PMID: 22775568 Eotaxin-1 not only induces MMP-3 gene expression but also promotes MMP-3 protein secretion through G protein-coupled eotaxin-1 receptor activities. PMID: 22114952 Pretreated CCD-11Lu cells with noncytotoxic doses (0.1-10 muM) of CAPE inhibited the production of eotaxin under stimulation of IL-4 and tnf-alpha.CAPE pretreatment decreased the amount of pSTAT6 and STAT6 DNA binding complexes in nuclear extracts. PMID: 21601544 In this study, eotaxin-1 -384 A>G or 67 G>A genotypes were not associated with susceptibility to Nasal Polyposis. PMID: 21825098 Data show that expression levels of CCL11 and CCR3 mRNA in the lesional skin of ALCL were significantly higher than those in normal skin. PMID: 21406396 After corticosteroid therapy, the expressions of Eotaxin and Eotaxin-2 in mucosal epithelia of nasal polyps were significantly decreased. PMID: 19522186 Eotaxin induces proliferation of nonasthmatic airway smooth muscle cells and decreases their rate of apoptosis. PMID: 21368236 The expression of Eotaxin-1 and -2 in nasal polyposis and polyps was dramatically higher than in controls. PMID: 17438849 Corticosteroid treatment of nasal polyps reduced expression of CCL11. PMID: 17438850 Measurements of eotaxin-1 in exhaled breath condensate of asthma patients may provide a useful diagnostic tool for detecting and monitoring airway inflammation and disease severity. PMID: 20704746 Serum CCL18 level was significantly decreased in epithelial ovarian cancer patients with early stages compared to those with late stages. PMID: 19937162 elevated levels of eotaxin in children with stable asthma; correlation with eosinophilia PMID: 20444156 Eotaxin may up-regulate the expression of VCAM-1 in vessel endothelium and promote adhesion and migration of eosinophils, as a result, to lead to the recurrence of nasal polyps. PMID: 16874958 Serum CCL11 was increased in ulcerative colitis (UC) and less in Crohn's disease (CD), whereas CCL24 and CCL26 were increased only in UC. Colon expression of the CCL's was higher in UC vs. CD, and was induced by Th2 cytokines in colon epithelial cells. PMID: 21077277 SOCS1 and 3 may control chemotaxis and adhesion PMID: 20934424

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.